Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer

Cancer Invest. 2010 Dec;28(10):1054-62. doi: 10.3109/07357907.2010.512602. Epub 2010 Sep 27.


Epidermal growth factor receptor (EGFR) is a target in head and neck cancer. High EGFR expression and phosphorylated EGFR predicts poor survival in head and neck cancer patients, but does not correlate with advanced stage disease. The aim of this study is to determine if clinical biological correlates are more accurate when different aspects of EGFR are evaluated in combination. We analyzed the EGFR phosphorylation, expression, and mutations in 60 primary head and neck tumors. We not only found that head and neck tumors with either truncated or activated EGFR tend to have higher tumor and nodal stage but also discovered two novel EGFR truncations.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / metabolism
  • Carcinoma, Squamous Cell / pathology*
  • DNA Mutational Analysis
  • ErbB Receptors / genetics*
  • ErbB Receptors / metabolism*
  • Female
  • Head and Neck Neoplasms / genetics*
  • Head and Neck Neoplasms / metabolism
  • Head and Neck Neoplasms / pathology*
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis / pathology
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Staging
  • Phosphorylation
  • Reverse Transcriptase Polymerase Chain Reaction


  • EGFR protein, human
  • ErbB Receptors